The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

Nature Reviews Microbiology

Volumn 11, Issue 7, 2013, Pages 482-496

  Bartenschlager, Ralf ^a,b   Lohmann, Volker ^a   Penin, Francois ^c,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b German Centre for Infectious Diseases (DZIF)   (Germany)

^c INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^d UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; BALAPIRAVIR; BI 207127; BOCEPREVIR; CLEMIZOLE; CYCLOPHILIN A; CYCLOSPORIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DACLATASVIR; GLYCOPROTEIN E1; GLYCOPROTEIN E2; MERICITABINE; MICRORNA 122; MK 5172; MK 517PSI 79772; N [5 (1 METHYL 1H PYRAZOL 4 YL) 2 NAPHTHOYL]GUANIDINE; NECEPREVIR; NESBUVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA; RG 1626; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; SCY 635; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CELL CLONE; CELL CULTURE; CELL STRUCTURE; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HOST CELL; HUMAN; LIFE CYCLE; MOLECULAR BIOLOGY; OPEN READING FRAME; PRIORITY JOURNAL; REPLICON; REVIEW; RNA REPLICATION; RNA SYNTHESIS; UNSPECIFIED SIDE EFFECT; VIRION; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84879420038     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3046     Document Type: Review

References (158)

1. Ascione, A., Tartaglione, T. & Di Costanzo, G. G. Natural history of chronic hepatitis C virus infection. Dig. Liver Dis. 39 (Suppl. 1), S4-S7 (2007). (Pubitemid 47532945)
2. Jacobson, I. M., Davis, G. L., El Serag, H., Negro, F. & Trepo, C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 8, 924-933 (2010).
3. Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. & Bell, B. P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45, 529-538 (2006). (Pubitemid 44307383)
4. Houghton, M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 239, 99-108 (2011).
5. Simmonds, P. The origin of hepatitis C virus. Curr. Top. Microbiol. Immunol. 369, 1-15 (2013).
6. Thimme, R., Binder, M. & Bartenschlager, R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol. Rev. 36, 663-683 (2012).
7. Sievert, W. et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 31 (Suppl. 2), 61-80 (2011).
8. Cornberg, M. et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 31 (Suppl. 2), 30-60 (2011).
9. Yahia, M. Global health: a uniquely Egyptian epidemic. Nature 474, S12-S13 (2011).
10. Schaefer, E. A. & Chung, R. T. The impact of human gene polymorphisms on HCV infection and disease outcome. Semin. Liver Dis. 31, 375-386 (2011).
11. Alvisi, G., Madan, V. & Bartenschlager, R. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol. 8, 258-269 (2011).
12. Murray, C. L. & Rice, C. M. Turning hepatitis C into a real virus. Annu. Rev. Microbiol. 65, 307-327 (2011).
13. Moradpour, D., Penin, F. & Rice, C. M. Replication of hepatitis C virus. Nature Rev. Microbiol. 5, 453-463 (2007). (Pubitemid 46780082)
14. Bartenschlager, R., Penin, F., Lohmann, V. & Andre, P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 19, 95-103 (2011).
15. Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999). (Pubitemid 29307577)
16. Lindenbach, B. D. Virion assembly and release. Curr. Top. Microbiol. Immunol. 369, 199-218 (2013).
17. Andre, P. et al. Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76, 6919-6928 (2002). (Pubitemid 41246207)
18. Chang, K. S., Jiang, J., Cai, Z. & Luo, G. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81, 13783-13793 (2007). (Pubitemid 350247871)
19. Lindenbach, B. D. et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl Acad. Sci. USA 103, 3805-3809 (2006). (Pubitemid 43376636)
20. Zeisel, M. B., Felmlee, D. J. & Baumert, T. F. Hepatitis C virus entry. Curr. Top. Microbiol. Immunol. 369, 87-112 (2013).
21. Blanchard, E. et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 80, 6964-6972 (2006). (Pubitemid 44025195)
22. Bartenschlager, R., Frese, M. & Pietschmann, T. Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res. 63, 71-180 (2004). (Pubitemid 39752303)
23. Ferraris, P., Blanchard, E. & Roingeard, P. Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes. J. Gen. Virol. 91, 2230-2237 (2010).
24. Romero-Brey, I. et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS. Pathog. 8, e1003056 (2012).
25. Gosert, R. et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 77, 5487-5492 (2003). (Pubitemid 36460961)
26. Lohmann, V. Hepatitis C virus RNA replication. Curr. Top. Microbiol. Immunol. 369, 167-198 (2013).
27. Miyanari, Y. et al. The lipid droplet is an important organelle for hepatitis C virus production. Nature Cell Biol. 9, 1089-1097 (2007). (Pubitemid 47338147)
28. Huang, H. et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl Acad. Sci. USA 104, 5848-5853 (2007). (Pubitemid 47175622)
29. Coller, K. E. et al. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS. Pathog. 8, e1002466 (2012).
30. Counihan, N. A., Rawlinson, S. M. & Lindenbach, B. D. Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS. Pathog. 7, e1002302 (2011).
31. Behrens, S. E., Tomei, L. & De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15, 12-22 (1996). (Pubitemid 26020384)
32. Lohmann, V., Korner, F., Herian, U. & Bartenschlager, R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71, 8416-8428 (1997). (Pubitemid 27446422)
33. Pawlotsky, J. M. Treatment of chronic hepatitis C: current and future. Curr. Top. Microbiol. Immunol. 369, 321-342 (2013).
34. Morikawa, K. et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J. Viral Hepat. 18, 305-315 (2011).
35. Phan, T., Kohlway, A., Dimberu, P., Pyle, A. M. & Lindenbach, B. D. The acidic domain of hepatitis C virus NS4A contributes to RNA replication and virus particle assembly. J. Virol. 85, 1193-1204 (2011).
36. Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005). (Pubitemid 41509355)
37. Li, K. et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA 102, 2992-2997 (2005). (Pubitemid 40299904)
38. Brass, V. et al. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc. Natl Acad. Sci. USA 105, 14545-14550 (2008).
39. Llinas-Brunet, M. et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 1713-1718 (1998). (Pubitemid 28341617)
40. Steinkuhler, C. et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37, 8899-8905 (1998). (Pubitemid 28299658)
41. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003). (Pubitemid 37442587)
42. Delang, L. et al. Hepatitis C virus-specific directly acting antiviral drugs. Curr. Top. Microbiol. Immunol. 369, 289-320 (2013).
43. Thompson, A. J., Locarnini, S. A. & Beard, M. R. Resistance to anti-HCV protease inhibitors. Curr. Opin. Virol. 1, 599-606 (2011).
44. Summa, V. et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56, 4161-4167 (2012).
45. Huang, M. et al. ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistance variants. Hepatology 52, 1204A (2010).
46. Romano, K. P. et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS. Pathog. 8, e1002832 (2012).
47. Tellinghuisen, T. L., Marcotrigiano, J., Gorbalenya, A. E. & Rice, C. M. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem. 279, 48576-48587 (2004). (Pubitemid 39625732)
48. Penin, F. et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 279, 40835-40843 (2004). (Pubitemid 39287681)
49. Tellinghuisen, T. L., Foss, K. L., Treadaway, J. C. & Rice, C. M. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J. Virol. 82, 1073-1083 (2008).
50. Masaki, T. et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol. 82, 7964-7976 (2008).
51. Appel, N. et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS. Pathog. 4, e1000035 (2008).
52. Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374-379 (2005). (Pubitemid 40745549)
53. Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A. & Cronin, C. N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83, 4395-4403 (2009).
54. Hwang, J. et al. Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J. Virol. 84, 12480-12491 (2010).
55. Appel, N., Schaller, T., Penin, F. & Bartenschlager, R. From structure to function: new insights into hepatitis C virus RNA replication. J. Biol. Chem. 281, 9833-9836 (2006). (Pubitemid 43864513)
56. Hanoulle, X. et al. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J. Biol. Chem. 284, 13589-13601 (2009).
57. Verdegem, D. et al. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic α-helical propensity and is a substrate of cyclophilin A. J. Biol. Chem. 286, 20441-20454 (2011).
58. de Chassey, B. et al. Hepatitis C virus infection protein network. Mol. Syst. Biol. 4, 230 (2008).
59. Yang, F. et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 82, 5269-5278 (2008). (Pubitemid 351705235)
60. Reiss, S. et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host. Microbe 9, 32-45 (2011).
61. Berger, K. L., Kelly, S. M., Jordan, T. X., Tartell, M. A. & Randall, G. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J. Virol. 85, 8870-8883 (2011).
62. Kaneko, T. et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Commun. 205, 320-326 (1994). (Pubitemid 24381628)
63. Quintavalle, M. et al. Hepatitis C virus NS5A is a direct substrate of casein kinase I-α, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors. J. Biol. Chem. 282, 5536-5544 (2007). (Pubitemid 47093729)
64. Tellinghuisen, T. L., Foss, K. L. & Treadaway, J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS. Pathog. 4, e1000032 (2008).
65. Chen, Y. C. et al. Polo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5A. J. Virol. 84, 7983-7993 (2010).
66. Macdonald, A. & Harris, M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85, 2485-2502 (2004). (Pubitemid 39214345)
67. Bianco, A. et al. Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS. Pathog. 8, e1002576 (2012).
68. Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96-100 (2010).
69. Guedj, J. et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl Acad. Sci. USA 110, 3991-3996 (2013).
70. Targett-Adams, P. et al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J. Virol. 85, 6353-6368 (2011).
71. Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96, 13034-13039 (1999).
72. Ago, H. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7, 1417-1426 (1999). (Pubitemid 29529882)
73. Lesburg, C.A. et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. 6, 937-943 (1999). (Pubitemid 29463307)
74. Moradpour, D. et al. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J. Virol. 78, 13278-13284 (2004). (Pubitemid 39507832)
75. Harrus, D. et al. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J. Biol. Chem. 285, 32906-32918 (2010).
76. Simister, P. et al. Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. J. Virol. 83, 11926-11939 (2009).
77. Mosley, R. T. et al. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J. Virol. 86, 6503-6511 (2012).
78. Madela, K. & McGuigan, C. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs. Future Med. Chem. 4, 625-650 (2012).
79. Shim, J., Larson, G., Lai, V., Naim, S. & Wu, J. Z. Canonical 3-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase. Antiviral Res. 58, 243-251 (2003). (Pubitemid 36589015)
80. Le Pogam, S. et al. In vitro selected Con1 subgenomic replicons resistant to 2-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351, 349-359 (2006). (Pubitemid 44108072)
81. Pawlotsky, J. M., Najera, I. & Jacobson, I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir. Ther. 17, 411-423 (2012).
82. Arnold, J. J. et al. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS. Pathog. 8, e1003030 (2012).
83. Pockros, P. J. et al. JUMP-C: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 28 Jan 2013 (doi:10.1002/hep.26275).
84. Sofia, M. J. et al. Discovery of a β-d-2-deoxy-2-α-fluoro-2- β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202-7218 (2010).
85. Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878-1887 (2013).
86. Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44 (2013).
87. Jacobson, I. M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1878-1887 (2013).
88. Powdrill, M. H., Bernatchez, J. A. & Gotte, M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2, 2169-2195 (2010).
89. Sarrazin, C., Hezode, C., Zeuzem, S. & Pawlotsky, J. M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56 (Suppl. 1), S88-S100 (2012).
90. Kukolj, G. et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 280, 39260-39267 (2005). (Pubitemid 41713879)
91. Biswal, B. K. et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. 280, 18202-18210 (2005). (Pubitemid 41389065)
92. Yi, G. et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob. Agents Chemother. 56, 830-837 (2012).
93. Poordad, F. et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 368, 45-53 (2013).
94. Howe, A. Y. et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 52, 3327-3338 (2008).
95. Shih, I. H. et al. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55, 4196-4203 (2011).
96. Hebner, C. M. et al. The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS ONE. 7, e39163 (2012).
97. Egger, D. et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76, 5974-5984 (2002). (Pubitemid 34556292)
98. Yu, G. Y., Lee, K. J., Gao, L. & Lai, M. M. Palmitoylation and polymerization of hepatitis C virus NS4B protein. J. Virol. 80, 6013-6023 (2006). (Pubitemid 43849179)
99. Gouttenoire, J. et al. Identification of a novel determinant for membrane association in hepatitis C virus nonstructural protein 4B. J. Virol. 83, 6257-6268 (2009).
100. Lundin, M., Lindstrom, H., Gronwall, C. & Persson, M. A. Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. J. Gen. Virol. 87, 3263-3272 (2006). (Pubitemid 44608361)
101. Gouttenoire, J., Roingeard, P., Penin, F. & Moradpour, D. Amphipathic α-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B. J. Virol. 84, 12529-12537 (2010).
102. Paul, D. et al. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J. Virol. 85, 6963-6976 (2011).
103. Einav, S. et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nature Biotech. 26, 1019-1027 (2008).
104. Thompson, A. A. et al. Biochemical characterization of recombinant hepatitis C virus nonstructural protein 4B: evidence for ATP/GTP hydrolysis and adenylate kinase activity. Biochemistry 48, 906-916 (2009).
105. Jones, D. M., Patel, A. H., Targett-Adams, P. & McLauchlan, J. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J. Virol. 83, 2163-2177 (2009).
106. Einav, S. et al. The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology 47, 827-835 (2008). (Pubitemid 351449674)
107. Cho, N. J. et al. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci. Transl. Med. 2, 15ra6 (2010).
108. Esser-Nobis, K. et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 57, 953-963 (2013).
109. Steinmann, E. & Pietschmann, T. Hepatitis C virus p7 - a viroporin crucial for virus assembly and an emerging target for antiviral therapy. Viruses 2, 2078-2095 (2010).
110. Luik, P. et al. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc. Natl Acad. Sci. USA 106, 12712-12716 (2009).
111. Chandler, D. E., Penin, F., Schulten, K. & Chipot, C. The p7 protein of hepatitis C virus forms structurally plastic, minimalist ion channels. PLoS. Comput. Biol. 8, e1002702 2012
112. Wozniak, A. L. et al. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS. Pathog. 6, e1001087 (2010).
113. Chatel-Chaix, L., Germain, M. A., Gotte, M. & Lamarre, D. Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr. Opin. Virol. 2, 588-598 (2012).
114. Zhu, H. et al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J. Infect. Dis. 205, 656-662 (2012).
115. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-1288 (2003). (Pubitemid 37314838)
116. Kaul, A. et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS. Pathog. 5, e1000546 (2009).
117. Coelmont, L. et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE. 5, e13687 (2010).
118. Liu, Z., Yang, F., Robotham, J. M. & Tang, H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. 83, 6554-6565 (2009).
119. Flisiak, R., Jaroszewicz, J., Flisiak, I. & Lapinski, T. Update on alisporivir in treatment of viral hepatitis C. Expert. Opin. Investig. Drugs 21, 375-382 (2012).
120. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577-1581 (2005). (Pubitemid 41266486)
121. Jopling, C. L., Schutz, S. & Sarnow, P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 4, 77-85 (2008). (Pubitemid 351944051)
122. Niepmann, M. Hepatitis C virus RNA translation. Curr. Top. Microbiol. Immunol. 369, 143-166 (2013).
123. Randall, G. et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl Acad. Sci. USA 104, 12884-12889 (2007). (Pubitemid 47255249)
124. Shimakami, T. et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc. Natl Acad. Sci. USA 109, 941-946 (2012).
125. Li, Y., Masaki, T., Yamane, D., McGivern, D. R. & Lemon, S. M. Competing and noncompeting activities of miR-122 and the 5 exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc. Natl Acad. Sci. USA 110, 1881-1886 (2013).
126. Henke, J. I. et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27, 3300-3310 (2008).
127. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
128. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694 (2013).
129. Tsai, W. C. et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884-2897 (2012).
130. Hsu, S. H. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122, 2871-2883 (2012).
131. Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
132. Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
133. Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
134. Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
135. Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
136. Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216-224 (2012).
137. Blight, K. J., Kolykhalov, A. A. & Rice, C. M. Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974 (2000).
138. Lohmann, V., Körner, F., Dobierzewska, A. & Bartenschlager, R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75, 1437-1449 (2001). (Pubitemid 32094702)
139. Bartenschlager, R. Hepatitis C virus replicons: potential role for drug development. Nature Rev. Drug Discov. 1, 911-916 (2002). (Pubitemid 37361585)
140. Saeed, M. et al. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob. Agents Chemother. 56, 5365-5373 (2012).
141. Saeed, M. et al. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 144, 56-58 (2013).
142. Peng, B. et al. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 144, 59-61 (2013).
143. Pietschmann, T. et al. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS. Pathog. 5, e1000475 (2009).
144. Bartosch, B., Dubuisson, J. & Cosset, F. L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197, 633-642 (2003). (Pubitemid 36314658)
145. Hsu, M. et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100, 7271-7276 (2003). (Pubitemid 36706428)
146. Bartosch, B. & Dubuisson, J. Recent advances in hepatitis C virus cell entry. Viruses 2, 692-709 (2010).
147. Kato, T. et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808-1817 (2003). (Pubitemid 37500445)
148. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791-796 (2005). (Pubitemid 41021213)
149. Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623-626 (2005). (Pubitemid 41033648)
150. Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294-9299 (2005). (Pubitemid 40923557)
151. Steinmann, E. & Pietschmann, T. Cell culture systems for hepatitis C virus. Curr. Top. Microbiol. Immunol. 369, 17-48 (2013).
152. Yi, M., Villanueva, R. A., Thomas, D. L., Wakita, T. & Lemon, S. M. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl Acad. Sci. USA 103, 2310-2315 (2006). (Pubitemid 43271666)
153. Li, Y. P. et al. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc. Natl Acad. Sci. USA 109, 19757-19762 (2012).
154. Li, Y. P. et al. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc. Natl Acad. Sci. USA 109, E1101-E1110 (2012).
155. Ahmad, J., Eng, F. J. & Branch, A. D. HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene. Semin. Liver Dis. 31, 347-355 (2011).
156. Fridell, R. A., Qiu, D., Wang, C., Valera, L. & Gao, M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54, 3641-3650 (2010).
157. Gouttenoire, J., Penin, F. & Moradpour, D. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev. Med. Virol. 20, 117-129 (2010).
158. Rai, R. & Deval, J. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res. 90, 93-101 (2011).